Clinical Application Value Of ATP-tumor Chemosensitivity Assay In The Chemotherapeutant Of Non-small Cell Lung Cancer

Background and Objective:Following the rising of tumor incidence,malignant tumor has became thecommon and frequently encountered disease which detriment human life andhealth.Lung cancer is one of the most frequent malignant tumor, non-small celllung cancer(NSCLC) account80%.Most patients with NSCLC are advancedstage when discovered.The chemotherapy program of platinum uniting the thirdgeneration new drugs considered to be the standard program for NSCLC. Thechemotherapy for tumor patient exist evident individual differenceclinically,different individual tumor tissue has different responsibility to thesame chemotherapy drugs or chemotherapy program,even the same pathotypeand stage,so chemotherapy effect is low. The key point of raising tumorchemotherapy effect efficiently is to detect the drugs sensitivity of tumor cellbefore the chemotherapy and screen efficient antitumor drug relatively,then toavoid blind chemotherapy and unnecessary adverse effect.ATP-tumorchemosensitivity assay is applicated extensively in the clinical tumor therapyresearch and drug screening study as advanced technology of tumor vitrochemosensitivity assay.At present domestic has the literature report ofATP-TCA used for guiding the solid tumor as breast cancer、gastric cancer、cancer of colon,but the report of ATP-TCA applied to Non-small cell lungcancer(NSCLC) pleural fluid is poor. This text detect the drug sensitivity tofive anticancer drugs of the patients with NSCLC pleural fluid specimen invitro by ATP-TCA,and to compare the association of clinical curative effect andvariability of clinical curative effect with adoption therapeutic regimenexperientially,approach the effect of ATP-TCA in chemotherapy of NSCLC. Methods:52samples of non-small cell lung cancers combined with pleural fluidwere obtained and divided into two groups. Susceptibility test group:32pleuraleffusion specimes were given respectively cisplatin(DDP), navelbine(NVB),paclitaxel(PTX), carboplatin(CBP), gemcitabine(GEM), paclitaxel andcarboplatin (PTX+CBP), navelbine and caboplatin(NVB+CBP), gemcitabineand carboplatin(GEM+CBP) in vitro to susceptibility test by ATP-TCA andselected treatment according to the results of in vitro susceptibility testingregimen.;Experience treatment group:20patients were given the standardprogram based on experience [Paclitaxel+Caboplatin] program.To appraise thecurative effect after two cycle treatment.Results:The appreciation rate is100%. Combined regimen is better than a singlemedication.GEM+CBP>PTX+CBP>NVB+CBP>NVB=PTX>GEM>CBP>DDP.The efficiency (65.6%) of chemotherapy test group according was highercompared with the efficiency (40.0%) of experience treatment group, P <0.05.Conclusion:It is different of the efficience of different chemotherapy drugs fornon-small cell lung cancer in vitro.ATP-TCA is a tumor chemosensitivity assayof sensitive and reliable,it can guide chemotherapy of NSCLC and achievebetter clinical efficacy.